Lompat ke isi utama
Main navigation
Tentang HIPRA
Tentang HIPRA
Jelajahi HIPRA
Sejarah
Keberlanjutan & CSR
HIPRA di seluruh dunia
Kesehatan Hewan
Kesehatan Manusia
Kesehatan Manusia
Bidang Terapeutik
COVID-19
Kesehatan pencernaan (GoodGut)
Proyek penelitian & pengembangan
Pengetahuan
Berita
Pers
Karier
Hubungi kami
Select your language
English
Español
Català
Português
Français
Italiano
Deutsch
Nederlands
Dansk
Polski
Türkçe
Ελληνικά
Русский
中文
한국어
Tiếng Việt
ไทย
Bahasa Indonesia
到台灣人
Cari
Negara
Global
Afganistan
Afrika Selatan
Albania
Aljazair
Amerika Serikat
Angola
Arab Saudi
Argentina
Armenia
Australia
Austria
Bahrain
Banglades
Belanda
Belarusia
Belgia
Benin
Bolivia
Bosnia-Herzegovina
Boswana
Brasil
Bulgaria
Burkina Faso
Burundi
Cile
Cina
Denmark
Ekuador
El Salvador
Eritrea
Estonia
Filipina
Finlandia
Georgia
Ghana
Guatemala
Guinea
Honduras
Hong Kong
Hongaria
India
Indonesia
Inggris
Iran
Irlandia
Islandia
Israel
Italia
Jepang
Jerman
Kamboja
Kamerun
Kanada
Kenya
Kolombia
Kongo (Brazzaville)
Kongo (Kinshasa)
Korea Selatan
Kosta Rika
Kroasia
Kuba
Kuwait
Laos
Latvia
Lebanon
Libia
Lichtenstein
Lituania
Luksemburg
Madagaskar
Makedonia
Malaysia
Mali
Malta
Maroko
Mauritania
Mauritius
Meksiko
Mesir
Mozambik
Myanmar
Nepal
Nigeria
Nikaragua
Norwegia
Oman
Pakistan
Panama
Pantai Gading
Paraguay
Peru
Polandia
Portugal
Prancis
Qatar
Republik Ceko
Republik Dominika
Rumania
Rusia
Rwanda
Selandia Baru
Senegal
Serbia
Singapura
Siprus
Slovenia
Slowakia
Spanyol
Sri Lanka
Sudan
Suriah
Swedia
Swiss
Taiwan
Tanzania
Tunisia
Turki
Uganda
Ukraina
Uni Emirat Arab
Uruguay
Usbekistan
Venezuela
Vietnam
Yaman
Yordania
Yunani
Zimbabwe
Kirim
Select your language
Bahasa Inggris
Bahasa Spanyol
Català
Português
Français
Italiano
Deutsch
Nederlands
Dansk
Polski
Türkçe
Ελληνικά
Русский
中文
한국어
Tiếng Việt
ไทย
Bahasa Indonesia
到台灣人
Cari
Negara
Global
Afganistan
Afrika Selatan
Albania
Aljazair
Amerika Serikat
Angola
Arab Saudi
Argentina
Armenia
Australia
Austria
Bahrain
Banglades
Belanda
Belarusia
Belgia
Benin
Bolivia
Bosnia-Herzegovina
Boswana
Brasil
Bulgaria
Burkina Faso
Burundi
Cile
Cina
Denmark
Ekuador
El Salvador
Eritrea
Estonia
Filipina
Finlandia
Georgia
Ghana
Guatemala
Guinea
Honduras
Hong Kong
Hongaria
India
Indonesia
Inggris
Iran
Irlandia
Islandia
Israel
Italia
Jepang
Jerman
Kamboja
Kamerun
Kanada
Kenya
Kolombia
Kongo (Brazzaville)
Kongo (Kinshasa)
Korea Selatan
Kosta Rika
Kroasia
Kuba
Kuwait
Laos
Latvia
Lebanon
Libia
Lichtenstein
Lituania
Luksemburg
Madagaskar
Makedonia
Malaysia
Mali
Malta
Maroko
Mauritania
Mauritius
Meksiko
Mesir
Mozambik
Myanmar
Nepal
Nigeria
Nikaragua
Norwegia
Oman
Pakistan
Panama
Pantai Gading
Paraguay
Peru
Polandia
Portugal
Prancis
Qatar
Republik Ceko
Republik Dominika
Rumania
Rusia
Rwanda
Selandia Baru
Senegal
Serbia
Singapura
Siprus
Slovenia
Slowakia
Spanyol
Sri Lanka
Sudan
Suriah
Swedia
Swiss
Taiwan
Tanzania
Tunisia
Turki
Uganda
Ukraina
Uni Emirat Arab
Uruguay
Usbekistan
Venezuela
Vietnam
Yaman
Yordania
Yunani
Zimbabwe
Kirim
Pencarian
Pencarian
Pengetahuan
All
Dokumen
Ilmu pengetahuan populer
Wawancara
Pendapat
Saring
Therapeutic areas
COVID-19
Kesehatan pencernaan
Apply
Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19
RBDCOV: The project’s origins and future endeavours
RBDCOV Talks HIPRA’s participation: In 5 minutes, what is a recombinant protein vaccine?
Preclinical evaluation of PHH-1V candidate against SARS-CoV-2 in non-human primates
Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate
Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial
Safety and immunogenicity of PHH-1V as booster vaccination through the Omicron era: results from a phase IIb open-label extension study up to 6 months
Immunogenicity and safety of an Omicron XBB.1.16 adapted vaccine for COVID-19: Interim results from a randomized, controlled, non-inferiority clinical trial
Muat lebih banyak